RT Journal Article
SR Electronic
T1 Hepatic Arterial Infusion of Oxaliplatin and L-Folinic Acid-modulated 5-Fluorouracil for Colorectal Cancer Liver Metastases
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 611
OP 619
VO 26
IS 1B
A1 NEYNS, BART
A1 VAN NIEUWENHOVE, YVES
A1 AERTS, MARIDI
A1 FONTAINE, CHRISTEL
A1 VERMEIJ, JOANNA
A1 SCHALLIER, DENNIS
A1 DECOSTER, LORE
A1 DE MEY, JOHAN
A1 VANDENBROUCKE, FREDERIK
A1 HOORENS, ANNE
A1 DELVAUX, GEORGES
A1 DE GRÉVE, JACQUES
YR 2006
UL http://ar.iiarjournals.org/content/26/1B/611.abstract
AB Background: Despite the progress made in the treatment of metastatic colorectal cancer (CRC), the results of second-line chemotherapy remain poor. Patients and Methods: The feasibility of hepatic arterial infusion (HAI) of oxaliplatin (100 mg/m2 over 6 h) followed by l-folinic acid (L-FA) (400 mg over 2 h i.v.)-modulated continuous HAI of 5-Fluorouracil (5-FU) (60 mg/kg over 42 h; q2w) as second-line chemotherapy for metastatic CRC limited to the liver was investigated. Results: A median of 9 treatment cycles were administered (range 4-14). Treatment-limiting toxicity consisted of: abdominal pain (3 patients), elevated liver enzymes accompanied by fatigue (3), elevated bilirubin (2), neutropenia (2), thrombocytopenia (3) and hypersensitivity to oxaliplatin (1). Normalization for >4 weeks of the carcinoembryonic antigen (CEA) level was documented in 3 patients and a decline of >50% for >4 weeks in 5 patients. A confirmed partial response (PR) was documented in 5, stable disease (SD) in 1 and progressive disease (PD) in 3 patients. In the latter 3 patients, lung metastases developed while a PR was observed in the liver metastases. A pathological complete response (CR) was documented in 2 patients. The median time to progression was 7.2 months (95% CI 1.3-13) and the median overall survival 18.3 months (95% CI 16.3-20.3). Conclusion: HAI of oxaliplatin plus CI5-FU/LV is feasible and merits further evaluation. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved